Page last updated: 2024-08-21

arsenic trioxide and Benign Neoplasms, Brain

arsenic trioxide has been researched along with Benign Neoplasms, Brain in 44 studies

Research

Studies (44)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	12 (27.27)	29.6817
2010's	29 (65.91)	24.3611
2020's	3 (6.82)	2.80

Authors

Authors	Studies
Defant, A; Mancini, I; Pancher, M; Quattrone, A; Rosatti, EF; Sidarovich, V; Sighel, D; Vigna, J	1
Alt, F; Backes, N; Bender, H; Brockmann, MA; Burhenne, J; Faber, J; Filipski, K; Fresnais, M; Glaser, M; Harter, PN; Huprich, S; Lehmann, N; Neu, MA; Paret, C; Pietsch, T; Roth, L; Russo, A; Seidmann, L; Sommer, C; Wagner, W; Wingerter, A	1
Cheng, Y; Fan, X; Li, F; Lu, Y; Ma, R; Piao, JG; Shi, X; Zheng, H; Zou, J	1
Chang, WC; Chao, KSC; Cheng, WC; Cho, CF; Hsiao, TH; Hsu, JL; Huang, YK; Hung, MC; Kuo, TT; Lai, LC; Lee, PC; Lin, CC; Lin, YS; Liu, YH; Lo, CC; Sher, YP; Shih, JY; Sun, X; Tseng, GC	1
Chandler, J; Fountas, L; Grimm, S; Helenowski, I; Kumthekar, P; Levy, R; Marymont, M; McCarthy, K; Mehta, M; Muro, K; Raizer, J	1
Bianchi, E; Bockstaller, M; Chan, JA; Chavez, L; Dorostkar, MM; Glass, R; Kool, M; Korshunov, A; Lambo, S; Meister, V; Merk, DJ; Neumann, JE; Neumann, P; Nowak, J; Renner-Müller, I; Schindler, P; Schneider, MR; Schüller, U; Shakarami, M; Sharma, T; Taketo, MM; von Hoff, K; Warmuth-Metz, M; Wefers, AK	1
Agarwal, N; Bloom, L; Bregy, A; Gersey, Z; Komotar, RJ; Osiason, AD; Shah, S; Thompson, JW	1
Bi, Y; Chen, X; Han, D; Ji, Z; Li, H; Liu, H; Liu, Y; Shen, C; Shi, C; Wang, C; Wu, J; Yang, G; Zhang, D; Zhao, S	1
Cavenee, WK; Cloughesy, TF; Iwanami, A; Mischel, PS	1
Aniceto, N; Astier, A; Becherirat, S; Gibaud, S; Lanhers, MC; Loboda, C; Socha, M; Yemloul, M	1
Chan, TC; Chang, WR; Chiou, SH; Fang, KM; Lin, TC; Liu, JJ; Ma, SZ; Tzeng, SF; Tzou, BC; Yang, CS	1
Bjerkvig, R; Huszthy, PC; Lah Turnšek, T; Motaln, H; Primon, M; Talasila, KM; Torkar, A	1
Albrecht, J; Alonso, FJ; Campos-Sandoval, JA; Cardona, C; Cheng, T; Colquhoun, A; Crisma, AR; Curi, R; Deberardinis, RJ; Gómez-García, MC; Higuero, A; Lobo, C; Márquez, J; Martín-Rufián, M; Matés, JM; Nascimento-Gomes, R; Segura, JA; Szeliga, M	1
Albert, L; Jhanwar-Uniyal, M; Karsy, M; Murali, R	1
Gülden, M; Klauser, E; Maser, E; Seibert, H; Seibert, S	1
Chen, XF; Han, DY; Sun, QX; Zhao, HB; Zhao, SG	1
Gwak, HS; Jin, HO; Jung, HW; Park, IC; Park, MJ; Rhee, CH; Woo, SH	1
Bi, Y; Chen, X; Cho, K; Hou, X; Li, C; Liu, H; Liu, Y; Peng, F; Shen, C; Wang, K; Wang, X; Yang, Z; Zhang, J; Zhang, W; Zhang, X; Zhao, S; Zheng, Z; Zhong, C; Zou, H	1
Fukami, T; Fukuda, M; Hojo, M; Inubushi, T; Miyamoto, S; Muraki, K; Nozaki, K; Onishi, N; Saiki, M; Satow, T; Saya, H; Shiino, A; Tanigaki, K; Yamada, S; Yoshimura, Y	1
Bao, S; Bian, XW; Cheng, L; Chu, CW; Fang, X; Huang, Z; Ke, SQ; Rich, JN; Shi, Y; Xie, Q; Zhou, W	1
Carrasquillo, JA; Cheung, NK; Kramer, K; Kushner, BH; Larson, SM; Modak, S; Pandit-Taskar, N; Zanzonico, P	1
El Malki, K; Faber, J; Gerhold-Ay, A; Kron, B; Lehmann, N; Neu, MA; Paret, C; Pietsch, T; Russo, A; Seidmann, L; Sommer, C; Theruvath, J; Wagner, W; Wingerter, A	1
Kawamoto, K; Li, Q; Li, Y; Zhao, S; Zhen, Y	1
Crocker, IR; Curran, WJ; McDonald, MW; Shu, HK	1
Lee, TC; Lee, YJ; Liu, SY; Wen, CY	1
Blinder, R; Chang, P; Galinsky, I; Ho, VT; Housman, E; Kesari, S; Lane, SW; Mullally, A; Stone, RM	1
Battastini, AM; Braganhol, E; Dalmolin, RJ; de Souza, LH; Gelain, DP; Moreira, JC; Pasquali, MA; Schröder, R; Zanotto-Filho, A	1
Lo-Coco, F; Sanz, MA	1
Sun, H; Zhang, S	1
Alimoghaddam, K; Dizaji, MZ; Ghaffari, SH; Ghavamzadeh, A; Malehmir, M	1
Chandler, JP; Grimm, SA; Jovanovic, B; Levy, RM; Marymont, M; McCarthy, K; Muro, K; Newman, SB; Raizer, JJ	1
Alhasan, MK; Lewis, MA; Liu, L; Magnusson, J; Mason, RP	1
Brannon, J; Dent, P; Fisher, PB; Gopalkrishnan, RV; Grant, S; Lebedeva, IV; Linehan, WM; McKinstry, R; Mitchell, C; Qiao, L; Rosenberg, E; Sarkar, D; Su, ZS; Valerie, K; Yacoub, A	1
Brown, SL; Kim, JH; Kolozsvary, A; Lew, YS; Ryu, S	1
Knox, SJ; Ning, S	2
Germano, IM; Kanzawa, T; Kondo, S; Kondo, Y; Xiao, L; Zhang, L	1
Fujita, N; Haga, N; Tsuruo, T	1
Ehninger, G; Helwig, A; Illmer, T; Klemm, M; Röllig, C; Schüttig, R; Wassilew, N	1
Karlsson, J; Påhlman, S; Pettersson, HM; Pietras, A; Øra, I	1
Choi, KS; Kim, EH; Kim, SU; Kwon, TK; Sohn, S; Yoon, MJ	1
Bael, TE; Gollob, JA; Peterson, BL	1
Dong, X; Liu, Y; Sun, X; Zhang, J; Zhang, X; Zhao, S; Zou, H	1
Kawakami, K; Kawamoto, K; Shi, C; Tsuchida, T; Zhao, S	1

Reviews

3 review(s) available for arsenic trioxide and Benign Neoplasms, Brain

Article	Year
Therapeutic Targeting of the Notch Pathway in Glioblastoma Multiforme. World neurosurgery, 2019, Volume: 131 Topics: ADAM Proteins; Amyloid Precursor Protein Secretases; Antineoplastic Agents; Arsenic Trioxide; Brain Neoplasms; Cell Hypoxia; Cell Line, Tumor; Gene Knockdown Techniques; Glioblastoma; Humans; Inhibitor of Differentiation Proteins; Kruppel-Like Transcription Factors; MicroRNAs; Microvessels; Molecular Targeted Therapy; Neoplasm Proteins; Netrin-1; Niclosamide; Receptors, Notch; Receptors, Urokinase Plasminogen Activator; Resveratrol; Signal Transduction; Tretinoin	2019
Modern approaches to treating acute promyelocytic leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Feb-10, Volume: 29, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Brain Neoplasms; Cytarabine; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Promyelocytic, Acute; Oxides; Recurrence; Reverse Transcriptase Polymerase Chain Reaction; Tretinoin	2011
Arsenic trioxide and neuroblastoma cytotoxicity. Journal of bioenergetics and biomembranes, 2007, Volume: 39, Issue:1 Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; bcl-2-Associated X Protein; Brain Neoplasms; Cell Death; Cell Differentiation; Drug Resistance, Neoplasm; Humans; Leukemia, Promyelocytic, Acute; Neuroblastoma; Oxides	2007

Trials

4 trial(s) available for arsenic trioxide and Benign Neoplasms, Brain

Article	Year
A phase II trial of arsenic trioxide and temozolomide in combination with radiation therapy for patients with malignant gliomas. Journal of neuro-oncology, 2017, Volume: 133, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Arsenic Trioxide; Arsenicals; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Drug Therapy, Combination; Female; Glioma; Humans; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Middle Aged; Oxides; Temozolomide; Treatment Outcome; Young Adult	2017
Arsenic Trioxide as a Radiation Sensitizer for 131I-Metaiodobenzylguanidine Therapy: Results of a Phase II Study. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2016, Volume: 57, Issue:2 Topics: 3-Iodobenzylguanidine; Adolescent; Adrenal Gland Neoplasms; Adult; Arsenic Trioxide; Arsenicals; Brain Neoplasms; Child; Child, Preschool; Drug Resistance, Neoplasm; Female; Humans; Male; Neuroblastoma; Oxides; Paraganglioma; Pheochromocytoma; Radiation-Sensitizing Agents; Radiopharmaceuticals; Survival Analysis; Treatment Outcome	2016
Phase I study of arsenic trioxide and temozolomide in combination with radiation therapy in patients with malignant gliomas. Journal of neuro-oncology, 2012, Volume: 110, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Dose Fractionation, Radiation; Female; Glioma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Oxides; Prognosis; Radiotherapy Dosage; Survival Rate; Temozolomide	2012
Phase II trial of arsenic trioxide and ascorbic acid with temozolomide in patients with metastatic melanoma with or without central nervous system metastases. Melanoma research, 2008, Volume: 18, Issue:2 Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Brain Neoplasms; Dacarbazine; Female; Humans; Male; Melanoma; Middle Aged; Oxides; Skin Neoplasms; Temozolomide	2008

Other Studies

37 other study(ies) available for arsenic trioxide and Benign Neoplasms, Brain

Article	Year
Expanding the Chemical Space of Arsenicin A-C Related Polyarsenicals and Evaluation of Some Analogs as Inhibitors of Glioblastoma Stem Cell Growth. Marine drugs, 2023, Mar-17, Volume: 21, Issue:3 Topics: Adamantane; Arsenic Trioxide; Brain Neoplasms; Cell Line, Tumor; Glioblastoma; Humans; Stem Cells	2023
Ceritinib-Induced Regression of an Insulin-Like Growth Factor-Driven Neuroepithelial Brain Tumor. International journal of molecular sciences, 2019, Aug-30, Volume: 20, Issue:17 Topics: Adult; Arsenic Trioxide; Base Sequence; Brain; Brain Neoplasms; Cell Line, Tumor; Child, Preschool; Chromosome Aberrations; DNA Methylation; Female; Germ-Line Mutation; Humans; Insulin-Like Growth Factor I; Molecular Targeted Therapy; Neoplasms, Neuroepithelial; Principal Component Analysis; Pyrimidines; Receptor, Notch1; Sulfones; Transcriptome; Tumor Suppressor Protein p53	2019
iRGD and TGN co-modified PAMAM for multi-targeted delivery of ATO to gliomas. Biochemical and biophysical research communications, 2020, 06-18, Volume: 527, Issue:1 Topics: Antineoplastic Agents; Arsenic Trioxide; Blood-Brain Barrier; Brain; Brain Neoplasms; Cell Line; Dendrimers; Drug Carriers; Drug Delivery Systems; Glioma; Humans; Oligopeptides; Tissue Distribution	2020
Targeting positive feedback between BASP1 and EGFR as a therapeutic strategy for lung cancer progression. Theranostics, 2020, Volume: 10, Issue:24 Topics: Adenocarcinoma of Lung; Animals; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Brain; Brain Neoplasms; Cell Line, Tumor; Cell Membrane; Drug Resistance, Neoplasm; ErbB Receptors; Feedback, Physiological; Gene Expression Profiling; Gene Knockdown Techniques; Humans; Kaplan-Meier Estimate; Lung; Lung Neoplasms; Membrane Proteins; Mice; Mutation; Nerve Tissue Proteins; Prognosis; Protein Kinase Inhibitors; Proteolysis; Repressor Proteins; Signal Transduction; Tissue Array Analysis; Xenograft Model Antitumor Assays	2020
A mouse model for embryonal tumors with multilayered rosettes uncovers the therapeutic potential of Sonic-hedgehog inhibitors. Nature medicine, 2017, Volume: 23, Issue:10 Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Disease Models, Animal; Down-Regulation; Gene Expression Profiling; Hedgehog Proteins; Humans; Immunohistochemistry; Mice; Mice, Transgenic; MicroRNAs; Neoplasms, Germ Cell and Embryonal; Oxides; Reverse Transcriptase Polymerase Chain Reaction; RNA-Binding Proteins; Signal Transduction; Wnt Signaling Pathway; Xenograft Model Antitumor Assays; Zinc Finger Protein GLI1	2017
Arsenic trioxide depletes cancer stem-like cells and inhibits repopulation of neurosphere derived from glioblastoma by downregulation of Notch pathway. Toxicology letters, 2013, Jun-20, Volume: 220, Issue:1 Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Basic Helix-Loop-Helix Transcription Factors; Brain Neoplasms; Cell Line; Cell Proliferation; Gene Expression Regulation, Neoplastic; Glioblastoma; Homeodomain Proteins; Humans; Neoplastic Stem Cells; Oxides; Phosphorylation; Proto-Oncogene Proteins c-akt; Receptors, Notch; Signal Transduction; STAT3 Transcription Factor; Transcription Factor HES-1	2013
Arsenic reverses glioblastoma resistance to mTOR-targeted therapies. Cell cycle (Georgetown, Tex.), 2013, May-15, Volume: 12, Issue:10 Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Brain Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Glioblastoma; Humans; Leukemia, Promyelocytic, Acute; Oxides; Quinazolines; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases	2013
The antitumor effects of an arsthinol-cyclodextrin complex in a heterotopic mouse model of glioma. European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 2013, Volume: 85, Issue:3 Pt A Topics: 2-Hydroxypropyl-beta-cyclodextrin; Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; beta-Cyclodextrins; Brain Neoplasms; Cell Line, Tumor; Excipients; Female; Glioma; Humans; Injections, Intraperitoneal; Magnetic Resonance Spectroscopy; Melarsoprol; Mice; Mice, Nude; Oxides; Xenograft Model Antitumor Assays	2013
Enhanced cell growth and tumorigenicity of rat glioma cells by stable expression of human CD133 through multiple molecular actions. Glia, 2013, Volume: 61, Issue:9 Topics: AC133 Antigen; Animals; Antigens, CD; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Basic Helix-Loop-Helix Transcription Factors; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Transformation, Neoplastic; Cerebral Cortex; Disease Models, Animal; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Formazans; Gene Expression Regulation, Neoplastic; Glioma; Glycoproteins; GTPase-Activating Proteins; Homeodomain Proteins; Humans; Intercellular Signaling Peptides and Proteins; Lentivirus; Oncogene Protein v-akt; Oxides; Peptides; Rats; Rats, Sprague-Dawley; Receptor, Notch1; RNA, Messenger; RNA, Small Interfering; Tetrazolium Salts; Time Factors; Transcription Factor HES-1; Transfection; Tumor Stem Cell Assay	2013
Cathepsin L silencing enhances arsenic trioxide mediated in vitro cytotoxicity and apoptosis in glioblastoma U87MG spheroids. Experimental cell research, 2013, Oct-15, Volume: 319, Issue:17 Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Brain Neoplasms; Cathepsin L; Cell Line, Tumor; Cell Survival; Gene Silencing; Glioblastoma; Humans; Oxides; Spheroids, Cellular; Tumor Cells, Cultured	2013
Both GLS silencing and GLS2 overexpression synergize with oxidative stress against proliferation of glioma cells. Journal of molecular medicine (Berlin, Germany), 2014, Volume: 92, Issue:3 Topics: Antioxidants; Apoptosis; Arsenic Trioxide; Arsenicals; BH3 Interacting Domain Death Agonist Protein; Brain Neoplasms; Cell Movement; Cell Proliferation; Cell Survival; Flow Cytometry; Gene Silencing; Glioma; Glutaminase; Glutathione; Humans; Mitochondria; Oxidative Stress; Oxides; Proto-Oncogene Proteins c-myc; Reactive Oxygen Species; Staining and Labeling	2014
The impact of arsenic trioxide and all-trans retinoic acid on p53 R273H-codon mutant glioblastoma. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2014, Volume: 35, Issue:5 Topics: Amino Acid Sequence; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Brain Neoplasms; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Codon; Extracellular Signal-Regulated MAP Kinases; Genes, p53; Glioblastoma; Humans; Molecular Sequence Data; Mutation; Neoplastic Stem Cells; Oxides; Tretinoin	2014
Additivity, antagonism, and synergy in arsenic trioxide-induced growth inhibition of C6 glioma cells: effects of genistein, quercetin and buthionine-sulfoximine. Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association, 2014, Volume: 67 Topics: Animals; Arsenic Trioxide; Arsenicals; Brain Neoplasms; Buthionine Sulfoximine; Cell Division; Cell Line, Tumor; Genistein; Glioma; Oxides; Quercetin; Rats	2014
Efficacy of intratumoral chemotherapy using arsenic trioxide (As2O3) sustained release tablets for the treatment of neurogliocytoma in nude mice. European review for medical and pharmacological sciences, 2014, Volume: 18, Issue:17 Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Brain Neoplasms; Delayed-Action Preparations; Disease Models, Animal; Drug Carriers; Glioma; Injection, Intratympanic; Lactic Acid; Mice; Mice, Inbred BALB C; Mice, Nude; Oxides; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Random Allocation; Tablets	2014
Tetraarsenic oxide-induced inhibition of malignant glioma cell invasion in vitro via a decrease in matrix metalloproteinase secretion and protein kinase B phosphorylation. Journal of neurosurgery, 2014, Volume: 121, Issue:6 Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Chromones; Enzyme Activation; Enzyme Inhibitors; Glioblastoma; Humans; Matrix Metalloproteinase 14; Matrix Metalloproteinase 2; Morpholines; Neoplasm Invasiveness; Oxides; Phosphorylation; Proto-Oncogene Proteins c-akt	2014
Impact of autophagy inhibition at different stages on cytotoxic effect of autophagy inducer in glioblastoma cells. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 2015, Volume: 35, Issue:4 Topics: Adenine; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Arsenic Trioxide; Arsenicals; Autophagy; Beclin-1; Blotting, Western; Brain Neoplasms; Caspase 3; Cell Line, Tumor; Chloroquine; Drug Synergism; Flow Cytometry; Glioblastoma; Humans; Membrane Proteins; Microscopy, Electron, Transmission; Oxides; rab GTP-Binding Proteins; rab7 GTP-Binding Proteins; RNA Interference; RNA, Small Interfering	2015
Arsenic trioxide sensitizes glioblastoma to a myc inhibitor. PloS one, 2015, Volume: 10, Issue:6 Topics: Aged; Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Brain Neoplasms; Cell Differentiation; Cell Proliferation; Disease Progression; ErbB Receptors; Female; Glioblastoma; Hedgehog Proteins; Humans; Magnetic Resonance Imaging; Male; Mice, SCID; Middle Aged; Neoplastic Stem Cells; Oxides; Proto-Oncogene Proteins c-myc; Signal Transduction; Thiazoles; Xenograft Model Antitumor Assays	2015
Arsenic trioxide disrupts glioma stem cells via promoting PML degradation to inhibit tumor growth. Oncotarget, 2015, Nov-10, Volume: 6, Issue:35 Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Brain Neoplasms; Cell Proliferation; Female; Glioblastoma; Humans; Mice, Inbred C57BL; Mice, Nude; Neoplastic Stem Cells; Nuclear Proteins; Oxides; Promyelocytic Leukemia Protein; Proteolysis; Proto-Oncogene Proteins c-myc; RNA Interference; Signal Transduction; Spheroids, Cellular; Time Factors; Transcription Factors; Transfection; Tumor Burden; Tumor Cells, Cultured; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays	2015
Activation of the basal cell carcinoma pathway in a patient with CNS HGNET-BCOR diagnosis: consequences for personalized targeted therapy. Oncotarget, 2016, Dec-13, Volume: 7, Issue:50 Topics: Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Axin Protein; Biomarkers, Tumor; Biopsy; Brain Neoplasms; Carcinoma, Basal Cell; Cell Survival; Child; DNA Mutational Analysis; Dose-Response Relationship, Drug; Genetic Predisposition to Disease; Hedgehog Proteins; Humans; Inhibitory Concentration 50; Magnetic Resonance Imaging; Male; Mutation; Neoplasms, Neuroepithelial; Oxides; Patched-1 Receptor; Phenotype; Polymorphism, Single Nucleotide; Precision Medicine; Predictive Value of Tests; Proto-Oncogene Proteins; Repressor Proteins; Smoothened Receptor; Tumor Cells, Cultured; Up-Regulation; Wnt Signaling Pathway; Zinc Finger Protein GLI1	2016
Arsenic trioxide-mediated Notch pathway inhibition depletes the cancer stem-like cell population in gliomas. Cancer letters, 2010, Jun-01, Volume: 292, Issue:1 Topics: Animals; Arsenic Trioxide; Arsenicals; Brain Neoplasms; Cell Line, Tumor; Down-Regulation; Glioblastoma; Humans; Intermediate Filament Proteins; Male; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Neoplastic Stem Cells; Nerve Tissue Proteins; Nestin; Oxides; Receptors, Notch; Signal Transduction	2010
Pattern of failure after limited margin radiotherapy and temozolomide for glioblastoma. International journal of radiation oncology, biology, physics, 2011, Jan-01, Volume: 79, Issue:1 Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Disease Progression; Disease-Free Survival; Dose Fractionation, Radiation; Female; Follow-Up Studies; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oxides; Radiotherapy Planning, Computer-Assisted; Temozolomide; Tomography, X-Ray Computed; Treatment Failure; Tumor Burden; Young Adult	2011
XPC silencing sensitizes glioma cells to arsenic trioxide via increased oxidative damage. Toxicological sciences : an official journal of the Society of Toxicology, 2010, Volume: 116, Issue:1 Topics: Arsenic Trioxide; Arsenicals; Autophagy; Base Sequence; Brain Neoplasms; Cell Line, Tumor; Cellular Senescence; DNA-Binding Proteins; Fluorescent Antibody Technique; Gene Silencing; Glioma; Humans; Oxidative Stress; Oxides; RNA, Small Interfering	2010
CNS relapse in acute promyeloctyic leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Aug-20, Volume: 28, Issue:24 Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Bone Marrow Neoplasms; Brain Neoplasms; Chromosomes, Human, Pair 15; Chromosomes, Human, Pair 17; Cranial Irradiation; Cytarabine; Drug Administration Schedule; Female; fms-Like Tyrosine Kinase 3; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Promyelocytic, Acute; Magnetic Resonance Imaging; Mercaptopurine; Methotrexate; Mutation; Nuclear Proteins; Oxides; Promyelocytic Leukemia Protein; Receptors, Retinoic Acid; Recurrence; Remission Induction; Retinoic Acid Receptor alpha; Reverse Transcriptase Polymerase Chain Reaction; Transcription Factors; Translocation, Genetic; Transplantation, Autologous; Treatment Outcome; Tretinoin; Tumor Suppressor Proteins	2010
NFκB inhibitors induce cell death in glioblastomas. Biochemical pharmacology, 2011, Feb-01, Volume: 81, Issue:3 Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Astrocytes; Brain Neoplasms; Cell Cycle; Cell Death; Cell Line, Tumor; Cisplatin; Curcumin; Doxorubicin; Drug Synergism; Glioblastoma; Humans; Leupeptins; Molecular Targeted Therapy; NF-kappa B; Nitriles; Oxides; Rats; Sesquiterpenes; Signal Transduction; Sulfones	2011
Arsenic trioxide regulates the apoptosis of glioma cell and glioma stem cell via down-regulation of stem cell marker Sox2. Biochemical and biophysical research communications, 2011, Jul-08, Volume: 410, Issue:3 Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Biomarkers; Brain Neoplasms; Cell Line, Tumor; Down-Regulation; Glioblastoma; Humans; Neoplastic Stem Cells; Oxides; SOXB1 Transcription Factors; Transcription, Genetic	2011
Synergistic effects of arsenic trioxide and silibinin on apoptosis and invasion in human glioblastoma U87MG cell line. Neurochemical research, 2012, Volume: 37, Issue:2 Topics: Apoptosis; Arsenic Trioxide; Arsenicals; Brain Neoplasms; Cell Line, Tumor; Drug Synergism; Glioblastoma; Humans; Neoplasm Invasiveness; Oxides; Silybin; Silymarin	2012
Comparison of optical and power Doppler ultrasound imaging for non-invasive evaluation of arsenic trioxide as a vascular disrupting agent in tumors. PloS one, 2012, Volume: 7, Issue:9 Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Blood Vessels; Brain Neoplasms; Breast Neoplasms; Cell Line, Tumor; Female; Humans; Male; Mice; Mice, Nude; Neoplasm Transplantation; Optical Imaging; Oxides; Prostatic Neoplasms; Ultrasonography, Doppler	2012
MDA-7 (interleukin-24) inhibits the proliferation of renal carcinoma cells and interacts with free radicals to promote cell death and loss of reproductive capacity. Molecular cancer therapeutics, 2003, Volume: 2, Issue:7 Topics: Acetylcysteine; Adenoviridae; Adjuvants, Immunologic; Apoptosis; Arsenic Trioxide; Arsenicals; bcl-X Protein; Brain Neoplasms; Carcinoma, Renal Cell; Caspases; Cell Division; Free Radical Scavengers; Free Radicals; Genes, Tumor Suppressor; Glioma; Glutathione Transferase; Humans; Interleukins; Kidney; Kidney Neoplasms; Oxides; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins c-bcl-2; Receptors, Virus; Recombinant Fusion Proteins; Tumor Cells, Cultured	2003
Arsenic trioxide enhances radiation response of 9L glioma in the rat brain. Radiation research, 2003, Volume: 160, Issue:6 Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Brain Neoplasms; Combined Modality Therapy; Glioma; Magnetic Resonance Imaging; Male; Oxides; Rats; Rats, Inbred F344	2003
Increased cure rate of glioblastoma using concurrent therapy with radiotherapy and arsenic trioxide. International journal of radiation oncology, biology, physics, 2004, Sep-01, Volume: 60, Issue:1 Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Brain Neoplasms; Cell Line, Tumor; Combined Modality Therapy; Glioblastoma; Humans; Mice; Mice, Nude; Oxides; Reactive Oxygen Species; Transplantation, Heterologous; Tumor Stem Cell Assay	2004
Arsenic trioxide induces autophagic cell death in malignant glioma cells by upregulation of mitochondrial cell death protein BNIP3. Oncogene, 2005, Feb-03, Volume: 24, Issue:6 Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Autophagy; Blotting, Western; Brain Neoplasms; Gene Expression Profiling; Glioma; Humans; Membrane Proteins; Oligonucleotide Array Sequence Analysis; Oxides; Proto-Oncogene Proteins; Reverse Transcriptase Polymerase Chain Reaction; Tumor Cells, Cultured; Up-Regulation	2005
Involvement of mitochondrial aggregation in arsenic trioxide (As2O3)-induced apoptosis in human glioblastoma cells. Cancer science, 2005, Volume: 96, Issue:11 Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; bcl-2-Associated X Protein; Brain Neoplasms; Caspases; Enzyme Activation; Glioblastoma; Humans; Membrane Potentials; Mitochondria; Oxides; Reactive Oxygen Species; Tumor Cells, Cultured	2005
Optimization of combination therapy of arsenic trioxide and fractionated radiotherapy for malignant glioma. International journal of radiation oncology, biology, physics, 2006, Jun-01, Volume: 65, Issue:2 Topics: Animals; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Brain Neoplasms; Combined Modality Therapy; Dose Fractionation, Radiation; Glioma; Humans; Male; Mice; Mice, Nude; Oxides; Transplantation, Heterologous; Tumor Cells, Cultured	2006
Arsenic-induced APL differentiation in cerebrospinal fluid. Leukemia research, 2007, Volume: 31, Issue:5 Topics: Adult; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Brain Neoplasms; Cell Differentiation; Cerebrospinal Fluid; Female; Humans; Leukemia, Promyelocytic, Acute; Leukocytes; Oxides; Remission Induction; Treatment Outcome	2007
Arsenic trioxide sensitizes human glioma cells, but not normal astrocytes, to TRAIL-induced apoptosis via CCAAT/enhancer-binding protein homologous protein-dependent DR5 up-regulation. Cancer research, 2008, Jan-01, Volume: 68, Issue:1 Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Astrocytes; Brain Neoplasms; Caspase 3; Glioma; Humans; Membrane Proteins; Oxides; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins; Receptors, TNF-Related Apoptosis-Inducing Ligand; RNA, Small Interfering; TNF-Related Apoptosis-Inducing Ligand; Transcription Factor CHOP; Tumor Cells, Cultured; Up-Regulation	2008
Intravenous administration of arsenic trioxide encapsulated in liposomes inhibits the growth of C6 gliomas in rat brains. Journal of chemotherapy (Florence, Italy), 2008, Volume: 20, Issue:2 Topics: Animals; Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Blotting, Western; Brain Neoplasms; Drug Stability; Glioma; Injections, Intravenous; Liposomes; Male; Microscopy, Electron; Neovascularization, Pathologic; Oxides; Rats; Rats, Wistar; Tissue Distribution	2008
Effect of As2O3 on cell cycle progression and cyclins D1 and B1 expression in two glioblastoma cell lines differing in p53 status. International journal of oncology, 2002, Volume: 21, Issue:1 Topics: Arsenic Trioxide; Arsenicals; Blotting, Western; Brain Neoplasms; Cell Cycle; Cell Division; Cyclin B; Cyclin B1; Cyclin D1; Dose-Response Relationship, Drug; Flow Cytometry; Glioblastoma; Humans; Oxides; Tumor Cells, Cultured; Tumor Suppressor Protein p53	2002